Ezra Cohen to Receptors, Vascular Endothelial Growth Factor
This is a "connection" page, showing publications Ezra Cohen has written about Receptors, Vascular Endothelial Growth Factor.
Connection Strength
0.471
-
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35.
Score: 0.115
-
New approaches to thyroid cancer. Clin Adv Hematol Oncol. 2012 Apr; 10(4):255-6.
Score: 0.100
-
Novel molecular targeted therapies for refractory thyroid cancer. Head Neck. 2012 May; 34(5):736-45.
Score: 0.094
-
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10; 26(29):4708-13.
Score: 0.077
-
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722.
Score: 0.054
-
Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1279-89.
Score: 0.030